OCULAR THERAPEUTIX, INC Operating Expenses
OCULAR THERAPEUTIX, INC (OCUL) reported Operating Expenses of $10.97 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2016-05-10
- OCULAR THERAPEUTIX, INC operating expenses for the quarter ending 2016-03-31 was $10.97M, a 45.47% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating expenses for the quarter ending 2015-12-31 was $10.71M, a 33.02% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating expenses for the quarter ending 2015-09-30 was $11.60M, a 67.70% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating expenses for the quarter ending 2015-06-30 was $10.09M, a 67.04% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating expenses for fiscal 2015 was $39.95M, a 43.35% increase from fiscal 2014.
- OCULAR THERAPEUTIX, INC operating expenses for fiscal 2014 was $27.87M, a 115.97% increase from fiscal 2013.
- OCULAR THERAPEUTIX, INC operating expenses for fiscal 2013 was $12.90M, a 5.69% decline from fiscal 2012.
- OCULAR THERAPEUTIX, INC operating expenses for fiscal 2012 was $13.68M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2016-03-31 | $10.97M 10-Q · filed 2016-05-10 | $21.68M derived: sum of 2 quarters · filed 2016-05-10 | $33.28M derived: sum of 3 quarters · filed 2016-05-10 | $43.38M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-12-31 | $10.71M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $22.31M derived: sum of 2 quarters · filed 2016-03-10 | $32.41M derived: sum of 3 quarters · filed 2016-03-10 | $39.95M 10-K · filed 2016-03-10 |
| 2015-09-30 | $11.60M 10-Q · filed 2015-11-10 | $21.70M derived: sum of 2 quarters · filed 2015-11-10 | $29.24M 10-Q · filed 2015-11-10 | $37.29M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-06-30 | $10.09M 10-Q · filed 2015-08-10 | $17.63M 10-Q · filed 2015-08-10 | $25.68M derived: sum of 3 quarters · filed 2016-05-10 | $32.60M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-03-31 | $7.54M 10-Q · filed 2016-05-10 | $15.59M derived: sum of 2 quarters · filed 2016-05-10 | $22.51M derived: sum of 3 quarters · filed 2016-05-10 | $28.55M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-31 | $8.05M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $14.97M derived: sum of 2 quarters · filed 2016-03-10 | $21.01M derived: sum of 3 quarters · filed 2016-03-10 | $27.87M 10-K · filed 2016-03-10 |
| 2014-09-30 | $6.92M 10-Q · filed 2015-11-10 | $12.96M derived: sum of 2 quarters · filed 2015-11-10 | $19.81M 10-Q · filed 2015-11-10 | $23.23M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $6.04M 10-Q · filed 2015-08-10 | $12.89M 10-Q · filed 2015-08-10 | $16.31M derived: sum of 3 quarters · filed 2016-03-10 | $19.75M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $6.85M 10-Q · filed 2015-05-15 | $10.27M derived: sum of 2 quarters · filed 2016-03-10 | $13.71M derived: sum of 3 quarters · filed 2016-03-10 | $16.70M derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $6.85M derived: sum of 2 quarters · filed 2016-03-10 | $9.84M derived: sum of 3 quarters · filed 2016-03-10 | $12.90M 10-K · filed 2016-03-10 |
| 2013-09-30 | $3.44M 10-Q · filed 2014-11-12 | $6.42M derived: sum of 2 quarters · filed 2014-11-12 | $9.48M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $2.99M 10-Q · filed 2014-08-29 | $6.05M 10-Q · filed 2014-08-29 | ||
| 2012-12-31 | $13.68M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |